Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label dose-finding study of BW-20507 injection in chronic hepatitis B
CTR20251532Phase 2Terminated
- Sponsor
- Bolin Pharma
- Start
- Apr 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BW-20507 in Chronic Hepatitis B (CHB), sponsored by Bolin Pharma. Started Apr 2025; status: terminated.
02
Drugs
BW-20507
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20251532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251532.